Skip to main content
. Author manuscript; available in PMC: 2019 Jun 24.
Published in final edited form as: Br J Haematol. 2019 Mar 3;185(4):679–690. doi: 10.1111/bjh.15818

Figure 2. SGI-110 alters the tumor microenvironment and enhances leukemia-specific immunity.

Figure 2.

C57BL/6J mice were retro-orbitally inoculated with 100,000 syngeneic TIB-49 AML cells that were stably transduced with GFP. The mice were then treated with 1mg/kg SGI-110 or diluent control. At day 12 following inoculation, BM and spleen cells were isolated and evaluated using flow cytometric analysis for (A) BM engraftment, (B) PD-1 expression of CD4+ cells in the spleen, (C) Myeloid-derived suppressor cell (MDSC) burden in the bone marrow and spleen, and (D) intracellular IFN-γ expression after exposure to autologous tumor lysate in the bone marrow and spleen.